It is worth noting in this regard that most BRD4/MYC blockers and especially the BRD4 degraders also exhibit strong direct anti-neoplastic effects on AML LSC [120,121], and may overcome multiple forms of LSC resistance in AML and CML (P.V., unpublished observation). This evidence concerns the gene BRD4 and acute myeloid leukemia.